Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Diagnostics & Research

IDEXX Laboratories, Inc. develops, manufactures, and distributes products for the companion animal veterinary, livestock and poultry, dairy, and water testing industries in the United States and internationally. It operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. The company offers point-of-care diagnostic solutions, blood and urine chemistry, hematology, immunoassay, urinalysis, cytology/morphology, and coagulation analyzers; and SNAP rapid assays test kits. It also provides commercial reference laboratory diagnostic and consulting services to veterinarians; veterinary consultation, telemedicine, and advisory services, including radiology, dental radiography, cardiology, internal medicine, and ultrasound consulting; Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, Quanti-Tray products, and Tecta system instruments; UV Viewer Plus, a UV light cabinet which aids in the visual interpretation of fluorescent-based water tests; and veterinary software and services for independent veterinary clinics and corporate groups. In addition, the company offers diagnostic tests, services, and related instrumentation to manage the health status of livestock and poultry; human medical diagnostic products and services; and VetConnect PLUS, a cloud-based technology that enables veterinarians to access and analyze patients, as well as operates VetLab Station. It markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.

Revenue projections:

Revenue projections for IDXX
Revenue projections for IDXX

Revenues for IDEXX Laboratories, Inc. are forecasted to decline from last year's levels, prompting caution among investors. When revenues fall, it can have a significant negative impact on the company's bottom line, reducing profitability and making the stock less attractive to risk-averse investors.

Financial Ratios:

currentRatio 1.231000
forwardPE 34.199707
debtToEquity 60.827000
earningsGrowth 0.179000
revenueGrowth 0.143000
grossMargins 0.617970
operatingMargins 0.297640
trailingEps 13.070000
forwardEps 16.397800

With a current ratio 1.231, IDXX demonstrates the ability to service its short-term debt without difficulty. The company's strong cash reserves and current assets ensure that it can meet its liabilities, reflecting financial stability and healthy liquidity.
IDXX's positive earnings and revenue growth signal that the company is expected to expand its business. This healthy financial trend reflects an optimistic outlook, suggesting continued growth in both sales and profits for IDXX.
Positive gross and operating margins for IDEXX Laboratories, Inc. suggest that the company is operating profitably. These margins highlight IDEXX Laboratories, Inc.'s efficiency in managing costs while maintaining healthy revenue streams, contributing to its overall financial strength.
IDXX's forward EPS exceeding its trailing EPS means that the company is expected to increase profitability in the current financial year. This reflects improved earnings potential, signaling that IDXX is likely to outperform its previous year's financial performance.

Price projections:

Price projections for IDXX
Price projections for IDXX

The price of IDXX has consistently been close to the lower limit of expectations. This trend may point to challenges in the company's performance, leading to concerns about its future growth potential.

Insider Transactions:

Insider Transactions for IDXX
Insider Transactions for IDXX


IDXX experienced 13 sell transactions with market price of 616.2523099459135 per share.There were no sell transactions during the given timeframe.More buys than sells near the current price levels of IDEXX Laboratories, Inc. might signal a favorable outlook for the stock. Investors seem to be showing confidence by purchasing more, potentially expecting positive future performance.

Recommendation changes over time:

Recommendations trend for IDXX
Recommendations trend for IDXX


Analysts have shown a buy bias for IDXX, signaling it as a strong investment choice. This positive outlook could motivate investors to allocate funds to IDXX, seeing it as a reliable and potentially profitable option, especially in an environment where the stock market is highly scrutinized.